Rhythm Pharmaceuticals, Inc. reported an insider ownership change for Alastair Garfield tied to the vesting of restricted stock units on July 1, 2026. The filing shows a transaction involving 12,208 shares of Rhythm common stock at a reported value of $110.41 per share. The shares came from restricted stock units, each of which represents a contingent right to receive one share of the company’s common stock. The RSUs were part of an award that vests in four equal annual installments: 25% on each of the first four anniversaries of July 1, 2024, provided Garfield continues to serve the company on each vesting date. The RSUs have no expiration date. In connection with the vesting, 2,150 shares were withheld at $110.41 per share to cover required withholding taxes. That tax-withholding transaction reduced the number of shares Garfield retained from the vesting event. Based on the reported figures, the net number of shares issued and retained after the withholding was 10,058 shares. The filing does not indicate an open-market sale by Garfield. Instead, the reported disposition reflects shares automatically withheld by the company for tax obligations arising from the RSU vesting. No transaction code is shown in the provided filing text, though the explanatory note identifies the 2,150-share disposition as tax withholding related to vested RSUs. The Form 4 was signed on July 2, 2026, by Stephen Vander Stoep as attorney-in-fact for Alastair Garfield.